- Home
- PSTV vs CVKD Comparison
PSTV vs CVKD Comparison
Compare PSTV & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- CVKD
- Stock Information
- Founded
- PSTV 1996
- CVKD 2022
- Country
- PSTV United States
- CVKD United States
- Employees
- PSTV N/A
- CVKD N/A
- Industry
- PSTV Medical/Dental Instruments
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- PSTV Health Care
- CVKD Health Care
- Exchange
- PSTV Nasdaq
- CVKD Nasdaq
- Market Cap
- PSTV 9.4M
- CVKD 17.1M
- IPO Year
- PSTV N/A
- CVKD 2023
- Fundamental
- Price
- PSTV $1.41
- CVKD $14.45
- Analyst Decision
- PSTV Strong Buy
- CVKD Strong Buy
- Analyst Count
- PSTV 2
- CVKD 2
- Target Price
- PSTV $14.00
- CVKD $52.50
- AVG Volume (30 Days)
- PSTV 84.6K
- CVKD 59.6K
- Earning Date
- PSTV 10-29-2024
- CVKD 11-08-2024
- Dividend Yield
- PSTV N/A
- CVKD N/A
- EPS Growth
- PSTV N/A
- CVKD N/A
- EPS
- PSTV N/A
- CVKD N/A
- Revenue
- PSTV $5,509,000.00
- CVKD N/A
- Revenue This Year
- PSTV $11.13
- CVKD N/A
- Revenue Next Year
- PSTV N/A
- CVKD N/A
- P/E Ratio
- PSTV N/A
- CVKD N/A
- Revenue Growth
- PSTV 113.20
- CVKD N/A
- 52 Week Low
- PSTV $0.97
- CVKD $5.40
- 52 Week High
- PSTV $2.78
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- PSTV 46.79
- CVKD 56.80
- Support Level
- PSTV $1.20
- CVKD $11.19
- Resistance Level
- PSTV $1.45
- CVKD $17.95
- Average True Range (ATR)
- PSTV 0.10
- CVKD 1.37
- MACD
- PSTV 0.01
- CVKD 0.10
- Stochastic Oscillator
- PSTV 57.37
- CVKD 49.64
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.